Incorporation of SPECT bone marrow imaging into intensity modulated whole-pelvic radiation therapy treatment planning for gynecologic malignancies.

BACKGROUND AND PURPOSE To incorporate single-photon emission computed tomography (SPECT) bone marrow (BM) imaging into the treatment planning process to reduce the volume of BM irradiated in gynecologic patients receiving intensity-modulated whole-pelvic radiation therapy (IM-WPRT). MATERIALS AND METHODS A planning CT scan was obtained of a patient with early stage endometrial cancer. The same patient also underwent a Tc-99m sulfur colloid SPECT scan of the pelvis. Tc-99m sulfur colloid is sequestered by the macrophages in the BM thereby identifying areas of active (red) BM. Using image fusion software, the SPECT scan was aligned with the planning CT scan and used to delineate regions of active BM. An IMRT plan was then generated to provide coverage of the planning target volume (PTV) while sparing areas of active BM and other normal pelvic structures. RESULTS The areas of high active BM density were observed predominantly in the lumbar vertebrae, sacrum and medial iliac crests. IMRT planning reduced the dose to these areas by 50% for doses greater than 30Gy compared to conventional planning. Furthermore, the IMRT plan did not compromise coverage of the PTV or sparing of normal tissues. CONCLUSIONS Our results suggest that SPECT-BM imaging is a useful adjunct to IMRT planning in gynecologic patients undergoing IM-WPRT.

[1]  John C Roeske,et al.  Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. , 2002, International journal of radiation oncology, biology, physics.

[2]  G. Thomas The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. , 2001, Seminars in oncology.

[3]  Linda Hong,et al.  IMRT of large fields: whole-abdomen irradiation. , 2001, International journal of radiation oncology, biology, physics.

[4]  H. Ishizaka,et al.  Water fraction of lumbar vertebral bone marrow estimated from chemical shift misregistration on MR imaging: normal variations with age and sex. , 1996, AJR. American journal of roentgenology.

[5]  S. Kalnicki,et al.  Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms. , 2003, Gynecologic oncology.

[6]  B. Maldague,et al.  MR assessment of red marrow distribution and composition in the proximal femur: correlation with clinical and laboratory parameters , 1997, Skeletal Radiology.

[7]  J. Roeske,et al.  Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. , 2000, International journal of radiation oncology, biology, physics.

[8]  J. Roeske,et al.  Intensity-modulated radiation therapy in gynecologic malignancies. , 2002, Current treatment options in oncology.

[9]  Chaney,et al.  Treatment Planning at the University of North Carolina at Chapel Hill. , 1992, Seminars in radiation oncology.

[10]  B N Bundy,et al.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. , 1999, The New England journal of medicine.

[11]  D Low,et al.  Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. , 2001, International journal of radiation oncology, biology, physics.

[12]  John C Roeske,et al.  A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  D. Hallahan,et al.  Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease. , 1995, International journal of radiation oncology, biology, physics.

[14]  John C Roeske,et al.  Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. , 2003, International journal of radiation oncology, biology, physics.

[15]  S Mutic,et al.  A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[16]  John C Roeske,et al.  Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. , 2001, International journal of radiation oncology, biology, physics.

[17]  S. Benedict,et al.  Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy. , 2001, International journal of radiation oncology, biology, physics.

[18]  A. Jhingran,et al.  New radiation techniques in gynecological cancer , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[19]  J. Roeske,et al.  Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. , 2001, Gynecologic oncology.

[20]  Jun Duan,et al.  IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. , 2004, International journal of radiation oncology, biology, physics.

[21]  C. Compton,et al.  Carcinoma of the anal canal. , 2000, The New England journal of medicine.

[22]  M. Thakur,et al.  Radiopharmaceuticals for spleen and bone marrow studies. , 1985, Seminars in nuclear medicine.

[23]  L Verhey,et al.  Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. , 1999, International journal of radiation oncology, biology, physics.

[24]  M. van Glabbeke,et al.  Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  John C Roeske,et al.  Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. , 2002, International journal of radiation oncology, biology, physics.

[26]  F. Datz,et al.  The clinical use of radionuclide bone marrow imaging. , 1985, Seminars in nuclear medicine.